Want to see MYGN full AI Analyst Report?
Total Valuation
Myriad Genetics has a market cap or net worth of $565.74M. The enterprise value is $500.78M.
Market Cap$565.74M
Enterprise Value$500.78M
Share Statistics
Myriad Genetics has 94,448,210 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding94,448,210
Owned by Insiders5.46%
Owned by Institutions4.84%
Financial Efficiency
Myriad Genetics’s return on equity (ROE) is -0.99 and return on invested capital (ROIC) is -10.83%.
Return on Equity (ROE)-0.99
Return on Assets (ROA)-0.52
Return on Invested Capital (ROIC)-10.83%
Return on Capital Employed (ROCE)-0.12
Revenue Per Employee302.57K
Profits Per Employee-134.28K
Employee Count2,725
Asset Turnover1.17
Inventory Turnover8.10
Valuation Ratios
The current PE Ratio of Myriad Genetics is ―. Myriad Genetics’s PEG ratio is -0.00859.
PE Ratio―
PS Ratio0.70
PB Ratio1.56
Price to Fair Value1.56
Price to FCF-22.41
Price to Operating Cash Flow233.86
PEG Ratio-0.00859
Income Statement
In the last 12 months, Myriad Genetics had revenue of 824.50M and earned -365.90M in profits. Earnings per share was -3.96.
Revenue824.50M
Gross Profit576.60M
Operating Income-67.80M
Pretax Income-395.10M
Net Income-365.90M
EBITDA-330.90M
Earnings Per Share (EPS)-3.96
Cash Flow
In the last 12 months, operating cash flow was 2.40M and capital expenditures -25.60M, giving a free cash flow of -23.20M billion.
Operating Cash Flow2.40M
Free Cash Flow-23.20M
Free Cash Flow per Share-0.25
Dividends & Yields
Myriad Genetics pays an annual dividend of $1.75, resulting in a dividend yield of ―
Dividend Per Share$1.75
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.27
52-Week Price Change13.23%
50-Day Moving Average4.52
200-Day Moving Average5.79
Relative Strength Index (RSI)73.15
Average Volume (3m)1.73M
Important Dates
Myriad Genetics upcoming earnings date is Jul 30, 2026, TBA (Confirmed).
Last Earnings DateMay 5, 2026
Next Earnings DateJul 30, 2026
Ex-Dividend Date―
Financial Position
Myriad Genetics as a current ratio of 2.49, with Debt / Equity ratio of 62.69%
Current Ratio2.49
Quick Ratio2.26
Debt to Market Cap0.37
Net Debt to EBITDA-0.18
Interest Coverage Ratio-6.46
Taxes
In the past 12 months, Myriad Genetics has paid -29.20M in taxes.
Income Tax-29.20M
Effective Tax Rate0.07
Enterprise Valuation
Myriad Genetics EV to EBITDA ratio is -1.92, with an EV/FCF ratio of -24.77.
EV to Sales0.77
EV to EBITDA-1.92
EV to Free Cash Flow-24.77
EV to Operating Cash Flow352.22
Balance Sheet
Myriad Genetics has $124.40M in cash and marketable securities with $211.50M in debt, giving a net cash position of -$87.10M billion.
Cash & Marketable Securities$124.40M
Total Debt$211.50M
Net Cash-$87.10M
Net Cash Per Share-$0.92
Tangible Book Value Per Share$1.75
Margins
Gross margin is 69.96%, with operating margin of -8.22%, and net profit margin of -44.38%.
Gross Margin69.96%
Operating Margin-8.22%
Pretax Margin-47.92%
Net Profit Margin-44.38%
EBITDA Margin-40.13%
EBIT Margin-46.65%
Analyst Forecast
The average price target for Myriad Genetics is $7.50, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$7.50
Price Target Upside47.64% Upside
Analyst ConsensusHold
Analyst Count6
Revenue Growth Forecast-0.28%
EPS Growth Forecast-286.80%